Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694561 | 0.80 | NOTUM (0.78) | NOTUMTLR8TP53MAPTALDH1A1 | |
| SCHEMBL4330245 | 0.80 | NPC1 (0.61) | NOTUMTLR8MAPTALDH1A1KDM4E | |
| SCHEMBL2610163 | 0.78 | NOTUM (0.75) | NOTUMTLR8TP53MAPTALDH1A1 | |
| SCHEMBL27846674 | 0.78 | NOTUM (0.56) | NOTUMTLR8MAPTALDH1A1KDM4E | |
| SCHEMBL9720227 | 0.77 | MAPT (0.70) | NOTUMMAPTALDH1A1GSK3BRAB9A | |
| SCHEMBL19814272 | 0.76 | NOTUM (0.53) | NOTUMTLR8MAPTALDH1A1KDM4E | |
| SCHEMBL3247152 | 0.74 | MAPT (0.51) | NOTUMTLR8MAPTALDH1A1KDM4E | |
| SCHEMBL16447783 | 0.74 | AAK1 (0.58) | NOTUMTLR8MAPTALDH1A1KDM4E | |
| SCHEMBL984873 | 0.71 | KCNJ1 (0.67) | NOTUMMAPTALDH1A1GSK3BKDM4E | |
| SCHEMBL4836703 | 0.71 | POLB (0.51) | MAPTALDH1A1KDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683085-B | Preparation method of aminated graphene oxide | 常州恒利宝纳米新材料科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-113683085-A | Preparation method of aminated graphene oxide | 常州恒利宝纳米新材料科技有限公司 | 2021-11-23 | — | — | CN | claimed |
| CN-102757402-A | Synthesizing method of 1,3,4-oxadiazole organic electroluminescent material | UNIV BEIJING CHEMICAL | 2012-10-31 | — | — | CN | claimed |
| CN-113683085-B | Preparation method of aminated graphene oxide | 常州恒利宝纳米新材料科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-113683085-A | Preparation method of aminated graphene oxide | 常州恒利宝纳米新材料科技有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-109336841-A | Using DMF as one step of carbon source construct 2-(4- nitrobenzophenone) -1,3,4- oxadiazoles method | 桂林理工大学 | 2019-02-15 | — | — | CN | disclosed |
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| CN-103097340-B | Therapeutically active compositions and methods of use thereof | 安吉奥斯医药品有限公司 | 2018-03-16 | — | — | CN | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| EP-0339854-B1 | SYNTHESIS OF N-T-ALKYL-1,2-DIACYLHYDRAZINES | ROHM AND HAAS COMPANY (US) | 1993-05-26 | — | — | EP | disclosed |
| EP-0339854-A2 | Synthesis of N-t-alkyl-1,2-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1989-11-02 | — | — | EP | disclosed |
| US-4505894-A | ANTIBIOTICS, BATERICIDES | BEECHAM GROUP LIMITED (GB) | 1985-03-19 | — | — | US | disclosed |
| US-4428958-A | OXAPENICILLINS, BETA-LACTAMASE INHIBITORS | BEECHAM GROUP LIMITED (GB) | 1984-01-31 | — | — | US | disclosed |
| EP-0003960-B1 | 6-SUBSTITUTED THIA-AZA-COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1983-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | NOTUM 2546/4885TLR8 4209/4885TP53 1546/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | NOTUM 4738/4885TLR8 4840/4885TP53 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.